Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.

Clinical development of imatinib in CML established continuous target inhibition as a paradigm for successful tyrosine kinase inhibitor (TKI) therapy. However, recent reports suggested that transient potent target inhibition of BCR-ABL by high-dose TKI (HD-TKI) pulse-exposure is sufficient to irreve...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel B Lipka, Marie-Christine Wagner, Marek Dziadosz, Tina Schnöder, Florian Heidel, Mirle Schemionek, Junia V Melo, Thomas Kindler, Carsten Müller-Tidow, Steffen Koschmieder, Thomas Fischer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0040853&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849470502981074944
author Daniel B Lipka
Marie-Christine Wagner
Marek Dziadosz
Tina Schnöder
Florian Heidel
Mirle Schemionek
Junia V Melo
Thomas Kindler
Carsten Müller-Tidow
Steffen Koschmieder
Thomas Fischer
author_facet Daniel B Lipka
Marie-Christine Wagner
Marek Dziadosz
Tina Schnöder
Florian Heidel
Mirle Schemionek
Junia V Melo
Thomas Kindler
Carsten Müller-Tidow
Steffen Koschmieder
Thomas Fischer
author_sort Daniel B Lipka
collection DOAJ
description Clinical development of imatinib in CML established continuous target inhibition as a paradigm for successful tyrosine kinase inhibitor (TKI) therapy. However, recent reports suggested that transient potent target inhibition of BCR-ABL by high-dose TKI (HD-TKI) pulse-exposure is sufficient to irreversibly commit cells to apoptosis. Here, we report a novel mechanism of prolonged intracellular TKI activity upon HD-TKI pulse-exposure (imatinib, dasatinib) in BCR-ABL-positive cells. Comprehensive mechanistic exploration revealed dramatic intracellular accumulation of TKIs which closely correlated with induction of apoptosis. Cells were rescued from apoptosis upon HD-TKI pulse either by repetitive drug wash-out or by overexpression of ABC-family drug transporters. Inhibition of ABCB1 restored sensitivity to HD-TKI pulse-exposure. Thus, our data provide evidence that intracellular drug retention crucially determines biological activity of imatinib and dasatinib. These studies may refine our current thinking on critical requirements of TKI dose and duration of target inhibition for biological activity of TKIs.
format Article
id doaj-art-797e76c3d7354db18c29dbd8b13b1d55
institution Kabale University
issn 1932-6203
language English
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-797e76c3d7354db18c29dbd8b13b1d552025-08-20T03:25:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0177e4085310.1371/journal.pone.0040853Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.Daniel B LipkaMarie-Christine WagnerMarek DziadoszTina SchnöderFlorian HeidelMirle SchemionekJunia V MeloThomas KindlerCarsten Müller-TidowSteffen KoschmiederThomas FischerClinical development of imatinib in CML established continuous target inhibition as a paradigm for successful tyrosine kinase inhibitor (TKI) therapy. However, recent reports suggested that transient potent target inhibition of BCR-ABL by high-dose TKI (HD-TKI) pulse-exposure is sufficient to irreversibly commit cells to apoptosis. Here, we report a novel mechanism of prolonged intracellular TKI activity upon HD-TKI pulse-exposure (imatinib, dasatinib) in BCR-ABL-positive cells. Comprehensive mechanistic exploration revealed dramatic intracellular accumulation of TKIs which closely correlated with induction of apoptosis. Cells were rescued from apoptosis upon HD-TKI pulse either by repetitive drug wash-out or by overexpression of ABC-family drug transporters. Inhibition of ABCB1 restored sensitivity to HD-TKI pulse-exposure. Thus, our data provide evidence that intracellular drug retention crucially determines biological activity of imatinib and dasatinib. These studies may refine our current thinking on critical requirements of TKI dose and duration of target inhibition for biological activity of TKIs.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0040853&type=printable
spellingShingle Daniel B Lipka
Marie-Christine Wagner
Marek Dziadosz
Tina Schnöder
Florian Heidel
Mirle Schemionek
Junia V Melo
Thomas Kindler
Carsten Müller-Tidow
Steffen Koschmieder
Thomas Fischer
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
PLoS ONE
title Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
title_full Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
title_fullStr Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
title_full_unstemmed Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
title_short Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
title_sort intracellular retention of abl kinase inhibitors determines commitment to apoptosis in cml cells
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0040853&type=printable
work_keys_str_mv AT danielblipka intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT mariechristinewagner intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT marekdziadosz intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT tinaschnoder intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT florianheidel intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT mirleschemionek intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT juniavmelo intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT thomaskindler intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT carstenmullertidow intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT steffenkoschmieder intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells
AT thomasfischer intracellularretentionofablkinaseinhibitorsdeterminescommitmenttoapoptosisincmlcells